Cellular plasticity and the neuroendocrine phenotype in prostate cancer

AH Davies, H Beltran, A Zoubeidi - Nature Reviews Urology, 2018 - nature.com
The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

[HTML][HTML] Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents

V Kannappan, M Ali, B Small, G Rajendran… - Frontiers in Molecular …, 2021 - frontiersin.org
Copper (Cu) plays a pivotal role in cancer progression by acting as a co-factor that regulates
the activity of many enzymes and structural proteins in cancer cells. Therefore, Cu-based …

Disulfiram: a novel repurposed drug for cancer therapy

C Lu, X Li, Y Ren, X Zhang - Cancer chemotherapy and pharmacology, 2021 - Springer
Cancer is a major health issue worldwide and the global burden of cancer is expected to
reduce the costs of treatment as well as prolong the survival time. One of the promising …

Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics

A Kirtonia, K Gala, SG Fernandes, G Pandya… - Seminars in cancer …, 2021 - Elsevier
Human malignancies are one of the major health-related issues though out the world and
anticipated to rise in the future. The development of novel drugs/agents requires a huge …

Toward precision medicine in glioblastoma: the promise and the challenges

MD Prados, SA Byron, NL Tran, JJ Phillips… - Neuro …, 2015 - academic.oup.com
Integrated sequencing strategies have provided a broader understanding of the genomic
landscape and molecular classifications of multiple cancer types and have identified various …

Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma

X Lun, JC Wells, N Grinshtein, JC King, X Hao… - Clinical Cancer …, 2016 - AACR
Purpose: Glioblastoma is one of the most lethal cancers in humans, and with existing
therapy, survival remains at 14.6 months. Current barriers to successful treatment include …

[HTML][HTML] Disulfiram: mechanisms, applications, and challenges

J Lanz, N Biniaz-Harris, M Kuvaldina, S Jain, K Lewis… - Antibiotics, 2023 - mdpi.com
Background: Since disulfiram's discovery in the 1940s and its FDA approval for alcohol use
disorder, other indications have been investigated. This review describes potential clinical …

[HTML][HTML] New drugs are not enough‑drug repositioning in oncology: An update

RG Armando… - … Journal of Oncology, 2020 - spandidos-publications.com
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that
are already known for use treating other diseases. The advantages of this are that several …

Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds

R Wuerth, S Thellung, A Bajetto, M Mazzanti, T Florio… - Drug discovery today, 2016 - Elsevier
Highlights•De novo anticancer drug discovery is challenging and repurposing in oncology is
a promising field.•Drug repositioning increasingly emerges as faster, cheaper and …

[HTML][HTML] Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells

P Liu, IS Kumar, S Brown, V Kannappan… - British journal of …, 2013 - nature.com
Background: Triple-negative breast cancer (TNBC) has significantly worse prognosis.
Acquired chemoresistance remains the major cause of therapeutic failure of TNBC. In clinic …